April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Outcomes of Ganciclovir 0.15% Ointment use in patients with Cytomegalovirus(CMV)-related anterior uveitis
Author Affiliations & Notes
  • John Wong
    Ophthalmology, National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore, Singapore
  • Stephen C B Teoh
    Ophthalmology, National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore, Singapore
  • Footnotes
    Commercial Relationships John Wong, None; Stephen Teoh, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 6291. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      John Wong, Stephen C B Teoh; Outcomes of Ganciclovir 0.15% Ointment use in patients with Cytomegalovirus(CMV)-related anterior uveitis. Invest. Ophthalmol. Vis. Sci. 2014;55(13):6291.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To evaluate the outcomes of treatment of CMV anterior uveitis patients with 0.15% ganciclovir ointment.

Methods: Retrospective review of the disease course in 31 patients (33 eyes) with positive aqueous polymerase-chain-reaction (PCR) for CMV, with 160 episodes of anterior uveitis flare dating from December 1992 to December 2012. All patients were treated with concomitant anti-inflammatory eyedrops. Intra-eye comparison was made for the disease course and recurrence rate, before and after ganciclovir ointment was started.

Results: The mean age at first presentation of uveitis in these patients was 57.5 (±12.6) years old. 28 patients (90.3%) are Chinese. Compared to without ganciclovir use, patients on ganciclovir ointment had a statistically significant fewer number of episodes of uveitis flare per person year (median -0.88 episodes/PY, p=0.029). The time to quiescence was not significantly affected by ganciclovir ointment use (median-1.25 days, p=0.610). In the survival analysis using the Cox regression model, topical ganciclovir use was associated with a lower risk of recurrence but this was not statistically significant (hazard ratio = 0.857, 95% C.I : 0.543 - 1.36, p = 0.511). Overall median time to recurrence was 290 days (95% C.I: 113 to 274 days) and 164 days (125 to 404 days)(p=0.492), with and without ganciclovir use, respectively.

Conclusions: Our results suggests that the use of 0.15% ganciclovir ointment significantly reduces the number of episodes of uveitis recurrence and is associated with prolonging the time to recurrence. The time-to-quiescence is not significantly affected by ganciclovir ointment use. Prospective studies with a larger number of patients are required to verify our findings.

Keywords: 492 cytomegalovirus • 746 uveitis-clinical/animal model  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×